New Hope for Serious Infections

Cidara is a clinical-stage biotechnology company focused on the development of novel anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives.

Company OverviewRezafunginCloudbreak™

Cidara is a clinical-stage biotechnology company focused on the development of novel anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives.

Company OverviewRezafunginCloudbreak™

Cidara News + Events

Cidara Therapeutics and Rutgers University Awarded $5.5 Million Grant from NIH

View the Announcement
Learn more about Cloudbreak™ ADCs

There is an urgent and growing need not only for improved anti-infectives but also for entirely new therapeutic approaches to treat and prevent fungal, bacterial, and viral pathogens, particularly for today’s increasingly complex and immunocompromised patients.

Our initial portfolio is comprised of proprietary product candidates for the treatment and prevention of serious fungal and bacterial infections.

Rezafungin (CD101 IV)

Rezafungin, a long-acting echinocandin antifungal, is the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal infections.

Cloudbreak™ Platform

The Cloudbreak immunotherapy discovery platform has the potential to do for infectious disease what immunotherapy has done for cancer — redirect the immune system to destroy fungal, bacterial and viral pathogens.